Liana Ly

Ms. Liana Ly

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Diabetology
Verified
Journal Article
Open access
PDF file
LLLiana Ly
Liana Ly
KVKaren L. Vo
Karen L. Vo
ACAudrey Christine Achacoso Cruel
Audrey Christine Achacoso Cruel
jay H shubrookjay H shubrook
jay H shubrook
Diabetes mellitus (DM) is a chronic metabolic disorder associated with late diagnosis due to the absence of early symptoms in patients. Cutaneous manifestations of DM often serve as indicators of insulin resistance and vary with disease progression, highlighting severity and systemic involvements. With an increasing global burden and rapidly rising prevalence, skin findings associated with DM have become more crucial for the rapid identification and treatment of underlying metabolic processes. However, current challenges in identification include inaccurate or missed detection in darker-skinned populations, which may be attributed to the lack of inclusion of diverse skin types in textbooks and research studies. This review provides clinicians with comprehensive updates on the diagnosis and treatment of cutaneous signs, complications, comorbidities, medication-associated side effects associated with DM, and the treatment of these manifestations.

17 January 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
BPBryan L. Peacker
Bryan L. Peacker
LLLiana Ly
Liana Ly
JHJonathan C. Hwang
Jonathan C. Hwang
KGKai Gravel-Pucillo
Kai Gravel-Pucillo
CZChristy Zheng
Christy Zheng
RHRebecca I. Hartman
Rebecca I. Hartman

16 October 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
DPDavid Perez
David Perez
BPBryan L. Peacker
Bryan L. Peacker
JHJonathan C. Hwang
Jonathan C. Hwang
LLLiana Ly
Liana Ly
CZChristy Zheng
Christy Zheng
RHRebecca I. Hartman
Rebecca I. Hartman
Although past genome-wide association studies (GWAS) have identified over 50 susceptible loci associated with vitiligo risk, few have systematically explored causality among potentially associated variants and genes. To address this, we analyzed summary statistics from 3 large-scale genomic resources, including the Million Veteran Program, United Kingdom Biobank, and FinnGen. Cases were defined using ICD-9 code 709.01 or ICD-10 code L80, including all studies that contributed genome-wide summary statistics and limiting analyses to loci with ≥1 common variant (minor allele frequency ≥1%). METAL was used to conduct a fixed effects inverse variance-weighted meta-analysis with kinship adjustment. Variant-to-gene (V2G) mapping was performed using the Open Targets V2G framework. Potentially causal effects were assessed using two-sample Mendelian randomization (MR) and genome-wide significant protein and expression quantitative trait locus instruments across 16 datasets. Genome-wide significance was defined as P < 5 x 10-8. Among 3,134 vitiligo cases and 1,383,912 controls, 5,482 genome-wide significant variants were identified, mapping to 23 distinct loci. MR found 18 potentially causative genes, 5 of which had not been previously associated with vitiligo: GDF11, ACO2, MEI1, OR2W1-AS1, GABBR1. To our knowledge, this study identifies several previously unreported potentially causal variants and genes associated with vitiligo, as well as pathogenic pathways beyond autoimmunity.